What the PCAC vote means for clinics and compounding pharmacies

Where things stand on October 4, 2026

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted on seven peptides. It recommended six for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, semax and epitalon, and rejected emideltide (news report) ¹. FDA's staff had proposed that none of them be included, form by form (FDA briefing document) ². Our report on the votes gives each count.

Since then, nothing has changed in law. As of the regulation current on September 1, 2026, the 503A list names six substances and no peptides (regulation) ³, and reporting in October 2026 confirms that none of the six has been added and that FDA must still decide whether to accept the advice and then go through a proposed rule, public comment and a final rule (news report) ¹. FDA has not announced that it will place them in Category 1 of its interim policy, which would signal it does not intend to act against pharmacies compounding them in the meantime.

What a 503A pharmacy can do now

Section 503A lets a pharmacy compound from a bulk substance only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the 503A list (statute) ⁴. None of the six peptides meets any of those conditions today, so compounding them falls outside the exemption that protects compounded drugs from the approval, manufacturing and labelling requirements of ordinary drugs.

Some law-firm commentary after the meeting predicted that FDA would exercise informal enforcement discretion in the interim for the substances the committee recommended (law-firm commentary) ⁵. That is a prediction, not a policy. As of October 4, 2026, FDA has published no such statement for these peptides, and a pharmacy relying on an expectation of leniency is relying on something the agency has not said. Our category guide explains what Category 1 status would mean if FDA did grant it.

What 503A pharmacies can lawfully compound is unaffected: substances with monographs, components of approved drugs, and the six listed substances, on valid prescriptions for individual patients. A pharmacy that has stopped compounding these peptides while it waits is in the same legal position it was in before the meeting, which is the position the law currently supports.

What clinics and prescribers can do now

A prescriber can write a prescription for almost anything, but without a lawful compounding route no pharmacy can lawfully fill one for these peptides, which our BPC-157 prescription article works through in detail. 'Research use only' supply is not a substitute. Ohio's Board of Pharmacy states that peptides such as BPC-157 and other Category 2 and 3 substances cannot be compounded under federal and state law, and has suspended more than 30 clinics and medical spas since early 2025 for a range of drug-handling violations (state board guidance) ⁶. Mississippi's medical, nursing and pharmacy boards say providers may not compound, administer, dispense, recommend or prescribe research-grade peptides at all, and that consent forms do not remove liability (joint board statement) ⁷.

Our state boards article covers those actions and Alabama's similar notice. For clinics, the practical position is unchanged by the vote: there is no lawful supply chain for these six peptides yet, and a clinic that stocks them is exposed to state discipline as well as federal law.

The uses FDA evaluated matter

Nominations are made for particular uses, and FDA evaluated each substance against them. For BPC-157, the meeting agenda lists the use evaluated as ulcerative colitis (FDA meeting page) ⁸. The committee's vote was a recommendation on that basis, and the briefing document weighs the evidence for the nominated uses and routes (FDA briefing document) ².

A listing would add the substance to the regulation, not a list of approved indications; the regulation itself states that listed substances lack adequate evidence of safety or effectiveness and that representing a compounded drug made from them as FDA-approved or endorsed misbrands it (regulation) ³. Clinics that market a listed peptide for tendon repair, weight loss or anti-ageing would be making claims no FDA review supports. The evidence for those uses is what our encyclopedia entries on BPC-157, TB-500 and MOTS-c set out.

The uses FDA reviewed for each peptide

FDA's meeting page lists the uses its staff reviewed for each substance (FDA meeting page) ⁸. They are narrower than the marketing around these peptides:

• BPC-157: ulcerative colitis.
• KPV: wound healing and inflammatory conditions.
• TB-500: wound healing.
• MOTS-c: obesity and osteoporosis.
• Semax: cerebral ischaemia, migraine and trigeminal neuralgia.
• Epitalon: insomnia.
• Emideltide (rejected): opioid withdrawal, chronic insomnia and narcolepsy.

Nothing on that list covers tendon or ligament repair, general recovery, anti-ageing or muscle building, the uses most often advertised. A clinic offering BPC-157 for a sports injury after any listing would be using a compounded drug for a purpose FDA's review did not consider.

What FDA's reviewers concluded

FDA's briefing document proposed, form by form, that each peptide not be included on the list, evaluating the free base and acetate forms of each substance separately (FDA briefing document) ². Reporting on the meeting summarised the reviewers' concern as short, underpowered studies that could not establish safety or effectiveness for the proposed uses, including limited human data for BPC-157 (news report) ¹. The committee weighed the same evidence and reached a different recommendation by narrow margins.

For clinicians, the reviewers' analysis is useful whichever way FDA decides: it is the most detailed public assessment of the human evidence for these peptides, and it is what any future rule will be built on.

Talking to patients while the rules are unsettled

Patients have read the headlines. A clear conversation covers four points: the July vote was advice and FDA has not acted; there is currently no lawful pharmacy source; research-grade products are outside any quality control and several state boards forbid clinicians from involvement with them (joint board statement) ⁷; and even a future listing would not establish that the peptide works for the patient's goal. Pointing patients to approved treatments with real evidence for their condition is, in most cases, the more useful part of the conversation.

Documenting that discussion protects both sides, particularly where a patient decides to obtain a product on their own.

If FDA lists them: what pharmacies would need

Listing would make the substance eligible, but the rest of section 503A would still apply. The bulk substance must be manufactured by an establishment registered with FDA, including registered foreign establishments, and must come with a valid certificate of analysis (statute) ⁴. The statute ties compounding to USP's pharmacy-compounding standards, which for injectables include sterile-compounding requirements, and limits it to an identified individual patient on a valid prescription (statute) ⁴.

That rules out the sources many clinics have used. Powder sold as a research chemical by an unregistered supplier would not meet the registered-establishment requirement, and a supplier's own certificate does not make it a registered manufacturer. Pharmacies preparing for a possible listing would need to identify registered manufacturers of pharmaceutical-grade BPC-157 or the other peptides, and confirm their certificates, before any rule takes effect.

Pharmacies would also need to decide what they will and will not compound. A peptide listed after review for ulcerative colitis does not come with dosing for other uses, and pharmacists share responsibility for what they dispense.

Marketing claims to avoid, now and after any listing

Some clinic marketing has already treated the vote as a green light. Several claims are wrong today and would stay wrong after a listing. 'FDA-approved BPC-157' is false and, for a compounded drug made from a listed substance, the regulation says representing it as FDA-approved or endorsed misbrands it (regulation) ³. 'Now legal to compound' is false as of October 4, 2026. 'Pharmaceutical-grade' means little unless the material comes from an FDA-registered manufacturer with a valid certificate, which is the statutory test (statute) ⁴.

Claims of benefit for uses FDA did not review, such as injury recovery or anti-ageing, would rest on the same limited evidence the agency's reviewers found wanting. State boards read clinic advertising too; Ohio's guidance grew out of citations its inspectors issued at clinics and medical spas (state board guidance) ⁶.

The paperwork a compliant pharmacy would keep

• Evidence that each bulk peptide's manufacturer is registered with FDA, including foreign establishments.
• The valid certificate of analysis for each lot, matched to the material received.
• The patient-specific prescription behind each compounded preparation.
• Sterile-compounding records and testing appropriate to injectables.
• Confirmation of licensure in each state the pharmacy ships to.

None of this is new for compounding pharmacies; what is new is applying it to substances that have so far been sourced largely outside the regulated supply chain.

What the vote does not touch

Approved peptide drugs are unaffected. GLP-1 medicines, teriparatide, leuprolide and the others in our encyclopedia marked approved are prescribed and dispensed exactly as before. So are compounded preparations of substances that already qualify under section 503A. The vote concerns only six unapproved peptides, and only their eligibility for compounding.

Outsourcing facilities

The vote concerns the 503A list only. Outsourcing facilities registered under section 503B have their own bulks list and process, and none of the six peptides is on it. A clinic hoping to buy office stock of a peptide from a 503B facility has no route from this vote. Our category guide covers the 503B side.

The state layer runs regardless

Whatever FDA decides, state boards license the pharmacies and clinicians involved and can act on their own timetable. Ohio's Board of Pharmacy already treats BPC-157 and other Category 2 and 3 substances as not compoundable and has used summary suspensions against clinics (state board guidance) ⁶. Mississippi's joint statement requires providers to buy all prescription products from board-permitted sources (joint board statement) ⁷. A federal listing would not oblige any board to withdraw stricter guidance overnight, and boards may want to see how FDA frames a final rule before revising theirs.

A pharmacy shipping across state lines therefore has two sets of rules to watch: the federal list and the guidance of every state it ships into.

How long it could take

No statute sets a deadline. FDA's first 503A rule came in February 2019, more than three years after it opened the nomination docket in October 2015, and a 2019 proposal to add five more substances has not been finalised (regulation) ³. Even if FDA moves quickly, a proposed rule must be published, comments taken and considered, and a final rule issued. Our guide to the nomination process walks through each step and where the 2026 cycle sits.

FDA can also choose not to list some or all of the six. Its own staff recommended against every one (FDA briefing document) ², and the committee's margins were narrow.

What clinics and pharmacies can do now to prepare

• Stop any use of research-grade or 'research use only' peptide supply, which several state boards treat as grounds for discipline.
• Track three places for change: FDA's interim-policy category lists, the Federal Register for a proposed 503A rule, and 21 CFR 216.23.
• Pharmacies: identify FDA-registered manufacturers and the documentation they provide, and review sterile-compounding capacity for injectable peptides.
• Clinicians: review the evidence for each peptide in the uses you would consider, and be ready to explain to patients that listing is not approval.
• Check your state board's guidance, which may be stricter than federal law for your licence.

What patients should take from this

If a clinic tells you BPC-157 or another of the six is now legal because of the July vote, that is not accurate as of October 4, 2026. The vote was advice, FDA has not acted, and no pharmacy has a lawful basis to compound these peptides (news report) ¹. Ask the clinic which pharmacy fills the prescription and under what authority; our guide to legitimate prescriptions explains how to check the answer.

Even after a listing, a compounded peptide would not be an approved drug, and its dose and benefit for most uses would rest on the limited evidence our encyclopedia entries describe.

Three ways this could go

FDA proposes listing some or all six. A proposed rule would open comment; nothing would change for pharmacies until the final rule, unless FDA also placed the substances in Category 1 in the meantime. Louisiana's 2026 law would then protect compliant compounding of them in that state from board prohibitions, as our state boards article explains.

FDA declines to list them. It could follow its staff's evaluation and propose excluding some or all, as it did for four substances now named as excluded in the regulation (regulation) ³. The current position would then become permanent until new evidence arrived.

FDA waits. The status quo continues: no lawful compounding, research-grade supply outside the law, and state boards acting against licensees who use it.

How it adds up (as of October 4, 2026)

The July 2026 committee vote recommended six peptides for the 503A list, but FDA has not proposed a rule, none is listed, and none has been moved to Category 1, so no 503A pharmacy or 503B facility has a lawful basis to compound them. If FDA does list them, pharmacies will need bulk material from FDA-registered manufacturers with valid certificates and must compound on valid prescriptions under USP standards, and listing will not be approval. Meanwhile state boards in Ohio, Mississippi and Alabama are acting against clinics and providers that use research-grade peptides.

Frequently asked questions

Can pharmacies compound BPC-157 now?

No. As of October 4, 2026, FDA has not added BPC-157 to the 503A list or moved it to Category 1, so a 503A pharmacy has no lawful basis to compound it despite the July 2026 committee vote.

Did the PCAC vote approve BPC-157?

No. The committee recommended listing it for compounding; only FDA rulemaking can list it, and listing is not FDA approval.

Is FDA allowing compounding while it decides?

FDA has announced no interim enforcement discretion for these peptides as of October 4, 2026. Some law firms predicted it might; that is not FDA policy.

What would pharmacies need if BPC-157 is listed?

Bulk BPC-157 from an FDA-registered manufacturer with a valid certificate of analysis, a valid prescription for an individual patient, and compliance with USP compounding standards.

Can a 503B outsourcing facility supply these peptides?

No. The vote concerns the 503A list; none of the six is on the separate 503B list.

Related on Grey Peptides

• The July 2026 PCAC votes
• How a substance gets on the 503A list
• State pharmacy boards and peptides
• Can a doctor prescribe BPC-157?

Sources

1. American Journal of Managed Care. "FDA Panel Backs 6 Peptides for Compounding" (October 2026); read October 4, 2026.
2. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (Docket FDA-2025-N-6895); read October 4, 2026. Source
3. 21 CFR 216.23 (eCFR, version current September 1, 2026); read October 4, 2026.
4. 21 U.S.C. 353a (Federal Food, Drug, and Cosmetic Act section 503A), subsections (a) and (b)(1); text read October 4, 2026.
5. McDermott Will & Emery. "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (law-firm commentary, July 2026); read October 4, 2026.
6. Ohio Board of Pharmacy. Ten Common Prescriber Clinic and Medical Spa Violations (guidance, updated December 8, 2025); read October 4, 2026.
7. Mississippi Board of Nursing, Board of Pharmacy and State Board of Medical Licensure. Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides, August 19, 2026; read October 4, 2026.
8. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: agenda (substances and uses evaluated) and briefing documents; read October 4, 2026. Source

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.